one
oldest
still
commonest
procedur
clinic
practic
allogen
blood
transfus
abt
fulli
support
avail
evid
last
decad
increas
concern
unfavor
outcom
associ
abt
anticip
futur
insuffi
cient
blood
suppli
awar
cost
direct
indirect
transfus
led
promot
patient
blood
manag
pbm
costeffect
strategi
benefi
cial
patient
well
societi
shander
et
al
pbm
program
util
seri
measur
proven
abil
reduc
abt
costeffect
despit
impact
pbm
patient
clinic
outcom
need
fulli
defi
ned
futur
studi
need
pbm
adopt
new
standard
care
complex
measur
undertaken
multiprofession
multidisciplinari
approach
medic
surgic
staff
order
perform
plan
surgeri
without
transfus
improv
patient
clinic
outcom
term
patient
blood
manag
issu
regard
one
ten
key
advanc
transfus
medicin
past
year
fulli
develop
last
decad
respons
differ
need
emerg
turn
millennium
time
scenario
show
allogen
blood
transfus
abt
univers
consid
part
standard
cure
major
elect
surgeri
relev
variat
exist
use
blood
blood
product
countri
within
hospit
countri
even
limit
lower
limb
arthroplasti
heterogen
likelihood
transfus
larg
rate
transfus
hip
knee
surgeri
respect
report
rosench
et
al
gombotz
et
al
number
suggest
standard
care
patient
undergo
elect
orthoped
surgeri
poorli
defi
ned
sinc
transfus
rate
appear
relat
case
mix
surgic
techniqu
anesthet
practic
driver
chang
blood
manag
differ
natur
contribut
strongli
motiv
intern
nation
author
approv
resolut
address
nation
govern
scientifi
c
societi
rec
european
council
recommend
member
state
arrang
appropri
regulatori
advisori
bodi
nation
local
level
order
implement
polici
encompass
use
altern
allogen
blood
transfus
prevent
strategi
reduc
blood
loss
world
health
assembl
resolut
avail
safeti
qualiti
blood
product
wha
bear
mind
patient
blood
manag
mean
surgeri
everi
reason
measur
taken
optim
patient
blood
volum
minim
patient
blood
loss
har
optim
patientspecifi
c
physiolog
toler
anemia
follow
guid
optim
clinic
use
three
pillar
patient
blood
manag
urg
member
state
promot
avail
transfus
altern
includ
appropri
autolog
transfus
patient
blood
manag
thereaft
regulatori
agenc
scientifi
c
societi
worldwid
develop
guidelin
recommend
aim
reduc
use
allogen
blood
transfus
also
implement
pbm
program
among
other
worthi
mention
australian
nation
blood
author
process
develop
six
comprehens
modul
pbm
guidelin
particular
modul
avail
http
regard
pbm
periop
set
itali
nation
scientifi
c
societi
transfus
medicin
simti
eman
complex
comprehens
recommend
liumbruno
et
al
b
c
also
use
guidelin
found
lealnov
et
al
histor
drive
advanc
toward
develop
pbm
known
unknown
risk
transfus
preserv
nation
blood
inventori
constraint
escal
cost
advers
effect
transfus
tradit
distinguish
acut
reaction
occur
minut
hour
delay
occur
within
day
month
acut
reaction
includ
acut
hemolyt
reaction
febril
nonhemolyt
reaction
allerg
reaction
transfusionassoci
circulatori
overload
taco
transfusionrel
acut
lung
injuri
trali
transfusionrel
sepsi
also
hyperkalemia
citrat
toxic
coagulopathi
hypothermia
may
occur
especi
case
massiv
transfus
delay
transfus
reaction
includ
delay
hemolyt
reaction
activ
immun
toward
blood
cell
antigen
iron
overload
transfusiontransmit
infect
autoimmun
posttransfus
purpura
transfusionassoci
graftversushost
diseas
advers
effect
among
mostli
ascrib
human
error
acut
hemolyt
reaction
taco
among
main
caus
transfusionassoci
death
well
known
thank
report
nationbas
hemovigil
system
haemovigil
requir
identifi
prevent
occurr
recurr
transfus
relat
unwant
event
increas
safeti
effi
caci
effi
cienci
blood
transfus
cover
activ
transfus
chain
donor
recipi
system
includ
monitor
identifi
cation
report
investig
analysi
advers
event
near
miss
reaction
relat
transfus
manufactur
http
wwwwhointbloodsafetyhaemovigilanceen
hemovigil
carri
extrem
import
conclus
recommend
entail
intrins
limit
essenti
use
incidentreport
methodolog
underreport
common
sinc
advers
effect
may
recogn
ascrib
transfus
due
lack
rigor
report
system
importantli
relev
advers
outcom
comprehend
even
wellestablish
hemovigil
system
requir
larg
clinic
studi
come
light
basi
sever
observ
studi
rct
caus
relationship
transfus
shown
unfavor
outcom
includ
higher
mortal
thrombot
event
organ
dysfunct
infect
delay
wound
heal
increas
length
hospit
stay
transfus
also
associ
cancer
recurr
insurg
nonhodgkin
lymphoma
comprehens
review
see
vamvaka
blajchman
shander
et
al
dose
relationship
present
complic
observ
administr
minim
amount
rbc
unit
rubinstein
et
al
highincom
countri
current
adopt
diagnost
measur
hbv
hcv
hiv
rel
transfusiontransmit
infect
dramat
reduc
hbv
rate
slightli
higher
around
prolong
window
period
serolog
convers
occult
hbv
infect
obi
reduct
possibl
introduct
triplex
hbvhcv
hiv
nat
test
countri
among
itali
basi
hbv
infect
preval
last
decad
west
nile
viru
wnv
constitut
grow
challeng
blood
bank
system
forc
nation
author
north
america
europ
implement
plan
either
test
refer
donat
adapt
base
nation
andor
local
epidemiolog
report
dynam
migrat
popul
tourism
also
taken
account
possibl
sourc
infect
epidemiolog
control
bodi
blood
manag
nation
author
refer
respect
report
transmiss
transfus
newli
emerg
reemerg
infect
due
protozoan
parasit
malaria
babesiosi
chaga
diseas
etc
virus
dengu
chikungunya
infl
uenc
strain
coronaviru
etc
prion
vcjd
matter
concern
implement
specifi
c
test
infrequ
infect
option
unaccept
cost
benefi
ratio
select
donor
guid
uptod
protocol
highincom
countri
ongo
demograph
dynam
character
describ
age
depend
ratio
burden
nonwork
popul
sustain
work
popul
oper
translat
fi
eld
total
transfus
depend
ratio
ttdr
hofmann
et
al
propos
nondon
popul
age
year
divid
donat
popul
multipli
index
suggest
sinc
age
patient
account
larg
part
rbc
transfus
patient
age
year
recent
past
year
ttdr
well
less
rapid
climb
expect
next
year
escal
sever
highincom
countri
farmer
et
al
perspect
blood
suppli
fulfi
lling
even
steadi
request
longer
taken
grant
accord
global
databas
blood
safeti
million
unit
blood
donat
approxim
half
highincom
countri
direct
cost
blood
compon
progress
increas
due
amelior
procedur
collect
test
process
consid
real
cost
transfus
long
seri
activ
involv
materi
resourc
technolog
personnel
transfus
servic
laboratori
ward
indirect
cost
taken
account
activitybas
cost
methodolog
shander
et
al
calcul
averag
transfus
singl
rbc
unit
cost
usa
europ
initi
approach
mainli
aim
reduc
use
abt
evolv
toward
patientcent
perspect
pbm
establish
order
ultim
amelior
patient
clinic
outcom
experi
still
brows
paper
discuss
realiz
pbm
continu
interpret
plain
concept
avoid
abt
even
reduct
abt
periop
cours
rate
remain
one
main
end
point
kind
data
easili
obtain
clinic
research
develop
instrument
order
deriv
outcom
relev
patient
pathway
pbm
base
three
pillar
detect
treatment
periop
anemia
reduct
surgic
blood
loss
periop
coagulopathi
har
optim
physiolog
toler
anemia
gener
popul
preval
anemia
increas
age
report
much
men
women
respect
age
year
guralnik
et
al
particular
among
candid
elect
orthoped
surgeri
one
three
fi
expect
anem
preadmiss
bierbaum
et
al
saleh
et
al
spahn
therefor
till
recent
presenc
lowgrad
anemia
accept
matter
fact
eventu
correct
liber
use
rbc
concentr
blood
compon
consid
safe
quickli
effect
readili
avail
rel
inexpens
consequ
preoper
anemia
predict
factor
periop
transfus
still
drive
relev
consumpt
blood
unit
khanna
et
al
myer
et
al
gruson
et
al
much
major
orthoped
hip
knee
surgeri
studi
conduct
north
england
well
et
al
preoper
anemia
independ
associ
increas
risk
periop
advers
outcom
noncardiac
surgeri
carson
et
al
gruson
et
al
dunn
et
al
beatti
et
al
wu
et
al
musallam
et
al
moreov
low
preoper
hemoglobin
concentr
high
patient
age
constantli
associ
increas
risk
transfus
addit
factor
repres
comorbid
low
bodi
weight
complex
surgeri
femal
sex
boralessa
et
al
barr
et
al
oxygen
suppli
essenti
aerob
metabol
employ
process
extract
energi
organ
molecul
multicellular
complex
organ
atmospher
oxygen
reach
tissu
diffus
specifi
calli
develop
organ
vascular
structur
liquid
system
blood
diffus
peripher
tissu
complex
organ
reli
higheffi
cienci
carrier
oxygen
bloodstream
atmospher
partial
pressur
oxygen
amount
dissolv
water
solvent
would
suffi
cient
life
therefor
mammal
presenc
adequ
quota
oxygen
inhal
air
anatom
function
integr
lung
vascular
adequ
blood
fl
ow
hemoglobin
content
critic
surviv
cell
even
simpl
organ
develop
mechan
sens
reduct
oxygen
deliveri
complex
organ
oxygen
sensor
multipl
exist
cell
hypoxiainduc
factor
hif
organel
aortic
carotid
chemoreceptor
organ
kidney
hypoxia
occur
mechan
becom
activ
ultim
lead
adapt
phenomena
observ
blood
loss
anemia
acut
anemia
partial
pressur
oxygen
arteri
blood
pao
hemoglobinoxygen
satur
sao
maxim
mean
increas
ventil
effi
cient
ventilationperfus
match
occur
nomedi
mechan
cardiovascular
system
undergo
fundament
modifi
cation
respons
acut
normovolem
anemia
activ
sympathet
nervou
system
stimul
vascular
chemoreceptor
heart
rate
stroke
volum
increas
result
cardiac
output
co
augment
threefold
presenc
intact
adapt
mechan
moreov
vasodil
occur
determin
reduct
system
vascular
resist
importantli
region
differ
co
establish
differenti
degre
vasodil
thu
vital
organ
initi
preserv
heart
brain
receiv
higher
proport
co
instead
kidney
appear
lower
margin
compens
becom
injur
earlier
insomuch
hemoglobin
concentr
drop
gdl
cardiac
surgeri
habib
et
al
karkouti
et
al
increas
co
also
relat
reduc
blood
viscos
increas
venou
return
associ
vasoconstrict
splanchnic
district
relev
adrenerg
activ
compens
mechan
highlight
consid
paradox
effect
blood
loss
increas
rate
periop
myocardi
infarct
van
klei
et
al
stroke
devereaux
et
al
follow
administr
adrenerg
antagonist
anoth
compens
mechan
tissu
hypoxia
increas
peripher
oxygen
extract
consequ
lower
hemoglobinoxygen
affi
niti
increas
reduc
ph
nomedi
event
overal
enlarg
capillari
bed
hand
organ
reduc
oxygen
demand
front
increas
consumpt
myocardium
human
toler
anemia
address
observ
studi
involv
patient
transfus
option
unavail
refus
also
experiment
investig
carri
voluntari
normovolemia
maintain
hb
concentr
low
gdl
toler
without
advers
system
effect
weiskopf
et
al
noncardiac
surgeri
hb
level
g
dl
associ
morbid
mortal
risk
mortal
increas
factor
everi
gdl
decrement
gdl
carson
et
al
healthi
subject
steadi
condit
oxygen
deliveri
meet
tissu
oxygen
demand
vo
exceed
fi
vefold
consumpt
rest
howev
relev
intraindividu
differ
oxygen
consumpt
depend
metabol
requir
importantli
wide
interindividu
differ
anemia
toler
exist
due
impair
ill
subject
part
compensatori
mechan
describ
surgeri
set
comorbid
primarili
cardiovascular
diseas
ultim
greatli
increas
rate
death
postop
anem
patient
carson
et
al
carson
et
al
periop
acut
blood
loss
anticip
medic
support
aim
maintain
normovolemia
optim
oxygen
deliveryoxygen
demand
ratio
order
prevent
ischem
organ
injuri
possibl
strategi
therefor
includ
measur
aim
increas
possibl
reduc
vo
sinc
cao
co
cao
arteri
oxygen
content
feasibl
approach
increas
cao
hyperox
ventil
aim
maxim
amount
ga
physic
dissolv
plasma
becom
relev
quota
avail
tissu
oxygen
presenc
low
hb
concentr
support
co
inotrop
drug
use
acut
normovolem
anemia
hand
reduc
oxygen
demand
obtain
neuromuscular
blockad
well
induct
anesthesia
depth
anesthesia
also
affect
anemia
toler
handl
tool
commonli
practic
see
meier
gombotz
current
exist
guidelin
cover
transfus
threshold
acut
anem
patient
reli
number
observ
studi
well
random
clinic
trial
issu
address
volum
hust
gentilini
ringressi
overal
complianc
avail
guidelin
compil
scientifi
c
societi
advisori
bodi
see
carson
et
al
retter
et
al
shander
et
al
main
cornerston
pbm
program
must
highlight
program
offer
must
state
benefi
ts
effect
costeffect
complet
pbm
program
fulli
proven
yet
diffi
cult
argu
overal
benefi
cial
outcom
program
encompass
sever
measur
aim
reduc
abt
improv
clinic
outcom
reduc
cost
nevertheless
although
effect
singl
measur
mostli
known
realli
anticip
effect
complex
measur
possibl
addict
synergist
even
paradox
counteract
studi
involv
larg
popul
need
order
address
question
form
crt
target
clinic
relev
outcom
form
registri
collect
safeti
effect
data
patient
manag
pbm
program
far
initi
involv
local
institut
demonstr
feasibl
implement
pbm
program
achiev
extrem
relev
goal
fewer
transfus
administ
reduc
mortal
complic
lenght
stay
lo
readmiss
cost
et
al
leahi
et
al
recent
publish
studi
soosman
et
al
combin
restrict
transfus
threshold
erythropoietin
administr
andor
autolog
blood
reinfus
report
effect
costeffect
erythropoietin
administr
show
lack
benefi
cell
salvagedrain
reinfus
patient
hb
level
gdl
pbm
therefor
simpli
transfus
altern
pbm
program
consid
complex
practic
measur
also
includ
altern
transfus
seri
tool
utiliz
pbm
program
list
tabl
singl
program
encompass
possibl
measur
inde
necessarili
altern
combin
prioriti
put
treatment
preoper
anemia
bloodspar
surgeri
techniqu
adequ
hemostasi
medic
support
optim
anemia
toler
adhes
protocol
concern
transfus
threshold
choic
measur
undertaken
done
basi
patient
characterist
expect
blood
loss
kind
surgeri
also
driven
organiz
featur
condit
patient
pathway
even
though
whole
process
valid
pbm
program
carri
pbm
elect
surgeri
regard
new
standard
care
reason
delay
implement
institut
mention
pbm
multiprofession
multidisciplinari
strategi
therefor
manageri
standpoint
implement
requir
draw
new
pathway
patient
candid
elect
orthoped
surgeri
involv
differ
specialist
among
anesthetist
play
major
role
draw
robust
includ
detail
algorithm
manag
patient
differ
featur
need
go
variou
step
eg
see
et
al
also
organ
continu
educ
control
commun
process
includ
elect
surgeri
preadmiss
assess
patient
clinic
condit
gener
perform
day
surgeri
potenti
benefi
ts
includ
increas
patient
safeti
reduc
cancel
delay
surgeri
reduc
lo
increas
qualiti
patient
experi
pillar
preanesthesia
evalu
medic
record
patient
interview
physic
examin
test
indic
nice
asa
major
surgeri
schedul
adult
includ
complet
blood
cell
count
blood
type
pbm
program
schedul
integr
ultim
aim
optim
patient
medic
health
prior
surgeri
ultim
avoid
unnecessari
transfus
weight
anemia
prognost
factor
unfavor
outcom
diagnosi
central
subsequ
correct
etiolog
heterogen
unexpect
diseas
chronic
kidney
failur
occult
malign
consid
case
referr
appropri
specialist
necessari
plan
elect
surgeri
overal
ironrestrict
erythropoiesi
relev
abnorm
condit
elderli
chronic
infl
ammat
common
candid
lower
limb
arthroplasti
spahn
consequ
iron
statu
must
assess
measur
blood
ferritin
tsat
togeth
infl
ammat
index
crp
test
order
contemporan
full
blood
cell
count
later
anem
patient
depend
organiz
constrain
royal
cornwal
hospit
collect
data
lead
discrimin
among
three
possibl
condit
absolut
iron
defi
cienci
due
blood
loss
nutrit
defi
cienci
malabsorpt
function
iron
defi
cienci
increas
erythron
iron
requir
treatment
esa
hemoglobinopathi
hemolyt
anemia
iron
sequestr
presenc
infl
ammat
hepcidindepend
mechan
weiss
goodnough
elderli
popul
also
vitamin
folat
defi
cienci
rel
common
bisb
et
al
saleh
et
al
suggest
order
dosag
refl
ex
test
defect
suspect
ie
macrocytosi
present
order
minim
blood
loss
surgeri
assess
hemorrhag
risk
constitut
prioriti
algorithm
score
risk
avail
tosetto
et
al
nichol
et
al
fundament
interview
person
famili
histori
bleed
disord
must
uncov
well
use
medica
prescrib
besid
anticoagul
antiplatelet
drug
agent
abl
interfer
hemostasi
includ
nsaid
serotonin
reuptak
inhibitor
antidepress
herbal
remedi
garlic
ginkgo
biloba
ginseng
other
angle
et
al
preoper
evalu
must
also
assess
transfus
strategi
begin
predict
need
abt
apposit
algorithm
elabor
mercuriali
inghilleri
noticewala
et
al
park
et
al
take
account
surgic
techniqu
procedur
durat
hemostat
measur
patient
featur
basi
altern
transfus
plan
includ
use
autolog
blood
andor
pharmacolog
treatment
major
surgeri
preadmiss
aborh
type
order
instead
use
red
cell
antibodi
screen
depend
patient
histori
previou
transfus
organiz
peculiar
ie
advis
pretransfus
test
crossmatch
blood
may
avail
time
constraint
surgeri
occur
shortli
admiss
nutrit
defi
cienci
treat
proper
vitamin
andor
miner
medica
besid
correct
diet
treatment
ironrestrict
erythropoiesi
particularli
import
preval
preoper
anemia
unfavor
consequ
base
avail
two
class
agent
iron
oral
iv
formul
erythropoiesisstimul
agent
esa
brief
oral
iron
therapi
toler
work
appropri
irondefi
cient
patient
unless
absorpt
defect
present
diagnosi
made
function
iron
defi
cienci
iron
sequestr
mix
anemia
iv
iron
therapi
may
necessari
particularli
presenc
system
infl
ammatori
respons
inhibit
gastrointestin
absorpt
caus
increas
hepcidin
level
present
iv
iron
includ
guidelin
recommend
pharmacolog
measur
aim
reduc
transfus
rate
lealnov
et
al
sever
formul
avail
iv
use
current
differ
anem
condit
highmolecularweight
iron
dextran
hmwd
abandon
favor
lowmolecularweight
iron
dextran
lmwd
lower
rate
advers
reaction
ferric
glucon
iron
sucros
formul
wide
use
chronic
kidney
diseas
advers
effect
rare
recent
introduc
ferumoxytol
requir
dilut
slow
iv
use
contrast
iron
sucros
sodium
ferric
glucon
ferric
carboxymaltos
iron
isomaltosid
still
cours
studi
applic
propos
well
ferumoxytol
total
dose
infus
slow
infus
g
european
medicin
agenc
committe
medicin
product
human
use
chmp
eman
new
recommend
manag
risk
allerg
reaction
intraven
ironcontain
medicin
indic
iv
iron
medicin
use
iron
supplement
given
mouth
use
work
staff
train
evalu
manag
anaphylact
anaphylactoid
reaction
must
immedi
avail
well
resuscit
facil
moreov
util
test
dose
underscor
period
observ
infus
prescrib
late
esa
fi
rst
approv
use
chronic
kidney
diseas
patient
mostli
continu
benefi
therapi
later
esa
also
approv
oncolog
patient
suffer
chemotherapyinduc
anemia
patient
candid
elect
surgeri
even
though
univers
particular
mani
european
countri
esa
preoper
use
approv
unless
preoper
autolog
blood
donat
pabd
schedul
recent
follow
postapprov
clinic
trial
target
risk
thrombot
advers
effect
esa
overal
increas
rate
morbid
mortal
limit
use
indic
respect
hb
level
appropri
antithrombot
prophylaxi
regulatori
agenc
use
preoper
esa
abl
increas
hb
level
equival
rbc
unit
produc
day
treatment
cours
pabd
program
unit
produc
time
compat
storag
use
surgeri
goodnough
et
al
effect
dosag
time
administr
debat
divers
schedul
use
low
dose
erythropoietin
ukg
period
suffi
cient
exert
signifi
cant
stimulu
erythropoiesi
san
et
al
even
singl
administr
erythropoietin
plu
iron
day
surgeri
found
effect
reduc
need
abt
cardiac
surgeri
yoo
et
al
aggress
schedul
employ
cours
pabd
program
rbc
mass
produc
period
directli
relat
erythropoietin
dosag
anticip
rbc
volum
ml
per
kg
x
x
equal
total
unit
erythropoietin
administ
per
kg
bodi
weight
goodnough
et
al
throughout
cours
esa
treatment
iron
supplement
necessari
maxim
rbc
product
stimul
esa
order
prevent
sever
blood
loss
withdraw
anticoagul
antiplatelet
drug
recommend
unless
critic
patient
safeti
usual
circumst
warfarin
aspirin
discontinu
day
surgeri
least
day
withdraw
necessari
clopidogrel
stop
aspirin
andor
clopidogrel
secondari
prevent
care
weight
case
case
discuss
prescrib
cardiologist
maintain
lowdos
aspirin
mostli
recommend
kort
et
al
royal
cornwal
hospit
experi
urgent
orthoped
surgeri
patient
antiplatelet
drug
reliev
gener
concern
excess
periop
bleed
colling
et
al
feeli
et
al
bridg
trial
target
bridg
anticoagul
still
ongo
use
nonprescrib
drug
herbal
remedi
possibl
interf
hemostat
process
discourag
classic
nsaid
short
halflif
usual
rais
concern
intraop
bleed
also
indic
withdraw
inhibitor
provid
advers
cardiac
effect
taken
account
serotonin
reuptak
inhibitor
antidepress
imput
enhanc
periop
bleed
far
clear
evid
increas
risk
abt
lack
advis
avoid
coadministr
aspirin
movig
et
al
van
haelst
et
al
recommend
behavior
regard
periop
use
drug
see
list
royal
cornwal
hospit
preoper
autolog
blood
donat
pabd
consist
collect
store
patient
blood
prior
surgeri
wide
practic
differ
surgic
set
offer
patient
main
altern
abt
inde
pabd
program
major
orthoped
surgeri
caus
reduct
risk
abt
rosench
et
al
carless
et
al
greater
effect
obtain
pabd
program
integr
treatment
esa
yet
overal
risk
transfus
increas
entail
increas
risk
cleric
error
well
kind
complic
also
present
pabd
taco
fever
chill
infect
possibl
immunomodul
disadvantag
overcollect
outdat
wast
taken
account
order
evalu
pabd
costbenefi
ratio
british
committe
standard
hematolog
eman
intern
recogn
guidelin
recommend
pabd
unless
specifi
c
condit
present
particular
patient
still
consider
candid
pabd
children
scoliosi
patient
refus
transfus
would
consent
pabd
bearer
rare
blood
group
polyimmun
pabd
program
combin
blood
salvag
may
benefi
cial
bilater
tka
boettner
et
al
normothermia
maintain
intraand
postop
order
sustain
physiolog
hemostasi
reduc
blood
loss
need
transfus
rajagopalan
et
al
method
fulfi
lling
requir
refer
specifi
c
literatur
acut
normovolem
hemodilut
consist
collect
unit
whole
blood
exchang
crystalloidcolloid
solut
perform
oper
theater
immedi
preced
surgeri
nt
seem
benefi
cial
orthoped
set
carless
et
al
consid
combin
bloodspar
measur
select
patient
undergo
spine
surgeri
shander
rijhwani
intraop
cell
salvag
restrict
set
concern
high
risk
intraop
bleed
arthroplasti
may
consid
hip
surgeri
subpopul
patient
expect
substanti
blood
loss
prevent
differ
mean
use
antifi
brinolyt
drug
ie
tranexam
acid
found
effect
minim
blood
loss
lower
limb
arthroplasti
remark
tka
also
prove
costeffect
see
henri
et
al
ker
et
al
irisson
et
al
concern
safeti
complet
reliev
would
justifi
ed
author
henri
et
al
sukeik
et
al
wherea
australian
author
solicit
postmarket
surveil
program
bruce
et
al
differ
schedul
use
administ
tranexam
acid
take
account
short
halflif
tka
tourniquet
use
administr
must
preced
releas
given
activ
fi
brinolysi
occur
thereaft
tranexam
acid
also
use
topic
tka
tha
obtain
signifi
cant
reduct
postop
blood
loss
without
relev
complic
wong
et
al
ishida
et
al
alshryda
et
al
b
tka
topic
appli
blood
compon
fi
brin
sealant
shown
safe
effect
reduc
total
blood
loss
abt
rate
liu
et
al
addit
author
evert
et
al
other
diiorio
et
al
also
found
platelet
gel
effect
consequ
defi
nitiv
recommend
topic
appli
blood
compon
present
drawn
tka
total
blood
loss
occur
postop
period
sehat
et
al
therefor
drainag
common
practic
aim
reduc
occurr
wound
hematoma
compress
vital
structur
meanwhil
permit
applic
salvagereinfus
system
date
two
kind
blood
salvag
system
consid
safe
effect
therefor
wide
use
includ
wash
blood
cell
discuss
featur
safeti
profi
le
two
system
see
et
al
recent
real
effi
caci
close
suction
drainag
question
emerg
caus
increas
need
allogen
blood
transfus
parker
et
al
instead
use
lowvacuum
drain
salvagereinfus
system
associ
reduc
rate
abt
lo
markar
et
al
haien
et
al
hand
use
antifi
brinolyt
drug
appear
effect
reinfus
drain
lower
risk
abt
sasanuma
et
al
signifi
cantli
reduc
volum
shed
blood
therefor
render
useless
collect
iwai
et
al
oremu
et
al
date
random
trial
compar
lowvacuum
drainblood
salvag
versu
drain
tka
still
insuffi
cient
one
recent
studi
design
show
drain
group
patient
present
higher
hb
level
postop
period
togeth
lower
net
blood
loss
horstmann
et
al
studi
power
enough
detect
signifi
cant
differ
either
abt
complic
rate
seem
reason
argu
postop
drain
use
especi
basi
expect
high
postop
blood
loss
divers
condit
hemophil
patient
kang
et
al
applic
lowvacuum
salvagereinfus
system
still
repres
best
option
order
prevent
abt
need
costeffect
debat
et
al
found
tka
postop
blood
salvag
would
also
costeffect
case
patient
present
surgeri
hb
g
dl
instead
patient
present
hb
g
dl
form
blood
salvag
would
useless
would
increas
cost
accord
soosman
et
al
inde
consid
institut
postsurgeri
strategi
gener
includ
drainag
would
afford
relev
cost
case
sporad
use
postop
blood
salvag
cost
devic
skill
mainten
use
iron
esa
also
propos
immedi
postop
treatment
aim
acceler
earli
recoveri
postop
anemia
trial
need
draw
conclus
use
one
two
differ
iv
iron
formul
postop
day
lower
limb
arthroplasti
effect
reduc
rate
transfus
without
increment
cost
et
al
conclus
discuss
focus
philosophi
pbm
instrument
use
draw
pbm
program
awar
diffi
culti
may
hamper
implement
solicit
manag
public
privat
institut
activ
promot
project
implement
benefi
cial
costeffect
pbm
pathway
pbm
strategi
develop
concern
safeti
blood
transfus
futur
blood
suppli
shortag
escal
cost
present
pbm
strategi
patient
center
aim
avoid
blood
transfus
also
target
patient
clinic
outcom
pbm
implement
requir
solid
design
includ
algorithm
manag
kind
patient
take
account
educ
commun
issu
prioriti
must
given
treatment
preoper
anemia
improv
anemia
toler
reduct
blood
loss
mean
bloodspar
surgic
techniqu
care
hemostasi
adher
protocol
administ
abt
despit
scarciti
evid
concern
whole
protocol
pbm
adequ
rational
exist
promot
wide
implement
pbm
program
studi
need
order
target
relev
clinic
outcom
